News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–48
Matches
48
Sources here
11
Companies here
1
Search results Stored financial headlines

Active search

48 matching headlines

Ticker or company: BLTEMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Earnings Main company 🇺🇸 United States

Belite Bio Inc (BLTE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Belite Bio Inc (BLTE), detailing analyst ratings, price targets, and historical and projected EPS. Based on 8 analysts' opinions, the stock has a "Buy" rating with an average target price of USD 210.50, representing a potential upside …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Belite Bio, Inc. ADR Revenue Breakdown – FWB:D01

This article focuses on the revenue breakdown for Belite Bio, Inc. ADR (D01) on the Frankfurt Stock Exchange. It indicates that the company's market is currently closed with no trades. The main content points to various financial data and tools available on TradingView for …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Market update Main company 🇺🇸 United States

Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases

A recent H.C. Wainwright conference highlighted advancements in treating inherited retinal diseases, particularly Stargardt disease and retinitis pigmentosa. Belite Bio presented positive data for its drug tinlarebant, showing a significant reduction in macular lesion growth for Stargardt disease, while Nanoscope Therapeutics showcased MCO-010 as …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Belite Bio (BLTE) Leerink’s Global Healthcare Conference 2025 Summary

This article summarizes Belite Bio's presentation at Leerink's Global Healthcare Conference 2025, focusing on their drug Tinlarebant for Stargardt disease and geographic atrophy. The summary details the disease background, drug mechanism, clinical trial designs (Phase II, DRAGON, DRAGON 2, and GA studies), and efficacy …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Analyst action Main company 🇺🇸 United States

Belite Bio stock price target maintained at $200 by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $200 price target for Belite Bio (NASDAQ:BLTE), citing positive secondary endpoint data from its Phase 3 DRAGON trial for tinlarebant in Stargardt disease type 1. The stock has seen a 170% return over the past …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
DirectorsTalk Interviews Analyst action Main company 🇺🇸 United States

Belite Bio, Inc (BLTE) Stock Analysis: A 37.73% Upside Potential in the Biotechnology Sector

Belite Bio, Inc (BLTE) is a clinical-stage biopharmaceutical company with a promising 37.73% upside potential, according to analyst ratings. The company is focused on developing therapies for Stargardt disease type 1 and geographic atrophy, with its lead product Tinlarebant (LBS-008) in phase 3 clinical …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Tinlarebant retinal marker stayed stable or fell ~2%; placebo rose 20%

Belite Bio reported additional positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The data, presented at ASRS 2026 Annual Meeting, showed that quantitative autofluorescence remained stable to slightly decreased in tinlarebant-treated subjects, while it increased …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Market update Main company 🇺🇸 United States

Belite Bio completes FDA filing for tinlarebant in Stargardt disease type 1

Belite Bio has completed its New Drug Application (NDA) filing with the FDA for tinlarebant, aiming to treat Stargardt disease type 1. This news brief, generated by AI, is for informational purposes only and references original content published by Belite Bio via GlobeNewswire.

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Regulatory and legal Main company 🇺🇸 United States

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

Belite Bio announced additional positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant in Stargardt disease type 1 (STGD1), which demonstrated a marked divergence in quantitative autofluorescence (qAF) between treatment groups. Tinlarebant showed stable to slightly decreased qAF values, while placebo …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

Responsive Playbooks and the BLTE Inflection

This article provides an in-depth AI-generated analysis of Belite Bio Inc (NASDAQ: BLTE), highlighting near-term weak sentiment challenging long-term strength. It presents institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes a multi-timeframe signal breakdown …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
markets.businessinsider.com Market update Main company 🇺🇸 United States

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Belite Bio, Inc. (NASDAQ: BLTE) announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026, at 3:00 pm ET. The clinical-stage drug development company focuses on novel therapeutics for degenerative retinal diseases like Stargardt disease type 1 and …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Belite Bio's July 22 Ophthalmology Panel Will Be Online

Belite Bio (NASDAQ: BLTE) announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET. The clinical-stage drug development company will join a panel discussion, and a live webcast with a 90-day replay will …

BLTE main company
Sharemaestro market context Price above Trend Line 52 weeks +152.8% · Next-week setup positive 55.4% BLTE stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context